Fundraising Fox

Ventus Therapeutics

Waltham, US · Founded 2019 · Delaware corporation · 4 known investors

ventustx.com ↗

Ventus discovers and develops small-molecule medicines using its proprietary ReSOLVE platform, focused on structure-based drug discovery. The company has advanced lead programs in Parkinson's disease and lupus through Phase 2 clinical trials.

AI & Machine LearningBiotechDeep TechHealthtechin /ventus-therapeutics

Founders & leadership

JL
Judith LiebermanCo-Founder, MD, PhD
DK
Daniel KoerwerExecutive Officer
JR
Josh ResnickDirector
JD
Jerel DavisDirector
SJ
Steven JamesDirector
BB
Brendan Bulik-SullivanDirector
MC
Michael CrackowerExecutive Officer
ZM
Zachary McNealyExecutive Officer
MB
Marcelo BigalExecutive Officer, Director

Investors · 4

Andreessen HorowitzMenlo Park · $500K – $50M
GV (Google Ventures)Mountain View · $250K – $50M
RA CapitalBoston
Versant VenturesreportedSan Francisco · $250K – $5Mvia Markus Warmuth · board

Reported raises · per SEC filings

Form D private placements
▶$70MraisedFeb 2022 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Steven JamesDirector
  • Daniel KoerwerExecutive Officer
  • Josh ResnickDirector
  • Markus WarmuthDirector
  • Michael CrackowerExecutive Officer
  • Jane Pritchett HendersonDirector
  • Jerel DavisDirector
  • Marcelo BigalExecutive Officer, Director
  • Dolca ThomasDirector
  • Brendan Bulik-SullivanDirector
  • John CassidyDirector
  • Zachary McNealyExecutive Officer
Offering amount
$140M
Amount sold
$70M
First sale
Feb 2022
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$100MraisedApr 2021 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Daniel KoerwerExecutive Officer
  • Josh ResnickDirector
  • Jerel DavisDirector
  • Steven JamesDirector
  • Brendan Bulik-SullivanDirector
  • Michael CrackowerExecutive Officer
  • Zachary McNealyExecutive Officer
  • Marcelo BigalExecutive Officer, Director
Offering amount
$100M
Amount sold
$100M
First sale
Mar 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.8MraisedMay 2020 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Jerel DavisDirector
  • Daniel KoerwerExecutive Officer
  • Hao WuDirector
  • Zachary McNealyExecutive Officer
  • Brendan Bulik-SullivanDirector
  • Marcelo BigalExecutive Officer, Director
Offering amount
$60.1M
Amount sold
$16.8M
First sale
Nov 2019
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news